<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626312</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0052</org_study_id>
    <secondary_id>NCI-2016-00006</secondary_id>
    <nct_id>NCT02626312</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function</brief_title>
  <official_title>Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out if the new method of giving radiation
      to the liver can be given safely to patients who already have liver problems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups and Radiation Administration:

      If you are found to be eligible to take part in this study, you will be assigned to a dose
      level of radiation based on when you join this study and on your screening test results. The
      dose level of radiation measures how much radiation the healthy parts of the liver and other
      organs can safely receive during radiation therapy. Two (2) dose levels of radiation will be
      tested. Three (3) to 6 participants will be enrolled at each dose level. The first group of
      participants will receive a standard dose level. The second group will receive either a
      higher or lower dose level than the group before it, depending on what side effects are seen.
      This will continue until the highest tolerable dose level is found. Up to 10 participants
      will receive radiation at the highest dose level that was found in the first part of the
      study.

      Radiation Therapy:

      You will receive radiation therapy up to 5 days a week for a total of either 15 or 25 doses,
      based on what the doctor thinks is in your best interest. Each dose of radiation you receive
      should take about 5-10 minutes, but the appointment for each dose of radiation will last
      about 1 hour. The study doctor can explain in more detail how the radiation will be given.

      You may receive chemotherapy as part of your standard care while you are on study if your
      regular doctor thinks it is in your best interest.

      Study Visits:

      One (1) time each week while you are receiving radiation:

        -  You will have a physical exam.

        -  Blood (up to 2 teaspoons) will be drawn for routine tests.

        -  You will be asked to complete the symptom questionnaire in person, over the internet, or
           by telephone.

      Length of Study Participation:

      You will receive radiation therapy for 15 or 25 treatments. You will no longer be able to
      receive radiation treatment if the disease gets worse, if intolerable side effects occur, if
      the study doctor thinks it is in your best interest, or if you are unable to follow study
      directions.

      Your participation on the study will be over after the follow-up visits.

      Follow-Up Visits:

      About 4-8 weeks after you complete radiation therapy, you will return to the clinic for
      follow-up visits. You will have follow-up visits every 3 months during the first year (+/- 1
      month) after radiation therapy, and every 4 months (+/- 1 month) in the second year after
      radiation therapy. If the disease gets worse or you start another therapy you will have
      follow-up visits every 6 months (+/1 month) for up to 2 years. At each visit you will have
      the following tests and procedures:

        -  You will have a physical exam.

        -  Blood (up to 2 teaspoons) will be drawn for routine tests.

        -  You will have an MRI, CT scan, and/or positron emission tomography (PET)/CT to check the
           status of the disease.

        -  Each week, you will fill out the symptoms questionnaire during the follow-up period in
           person, over the internet, or by telephone. This questionnaire should take about 10
           minutes.

      This is an investigational study. Radiation therapy is delivered using FDA-approved and
      commercially available methods. Combining advanced radiation therapy techniques with
      functional imaging for patients with liver cancer and with decreased liver function is
      considered investigational.

      Up to 88 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Dose Constraints (MDC) for Two Radiation Regimens</measure>
    <time_frame>2 months after completion of radiation therapy</time_frame>
    <description>A dose limiting toxicity (DLT) is any grade 3 hypoalbuminemia (&lt;2 g/dl), any grade 3 increase in INR (&gt;2.5 x upper limit of normal or &gt;2.5 times above baseline if on anticoagulation), any grade 3 increase in bilirubin (&gt;3.0 to 10.0 x upper limit of normal), any grade 3 ascites (severe symptoms; invasive intervention indicated), any grade 4 hepatic failure (moderate to severe encephalopathy), or any other grade 4 toxicity related to radiation of the liver.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Disease Control Rate</measure>
    <time_frame>2 years</time_frame>
    <description>The Kaplan Meier method used to estimate 2-year local disease control rate and probability of overall survival.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Impaired Liver Function</condition>
  <arm_group>
    <arm_group_label>Advanced Cirrhosis Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.
Participant may receive chemotherapy while on study based on decision of physician.
Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Functional Liver Volume Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.
Participant may receive chemotherapy while on study based on decision of physician.
Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prior Liver Directed Radiation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.
Participant may receive chemotherapy while on study based on decision of physician.
Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.</description>
    <arm_group_label>Advanced Cirrhosis Group</arm_group_label>
    <arm_group_label>Low Functional Liver Volume Group</arm_group_label>
    <arm_group_label>Prior Liver Directed Radiation Group</arm_group_label>
    <other_name>XRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Participant may receive chemotherapy while on study based on decision of physician.</description>
    <arm_group_label>Advanced Cirrhosis Group</arm_group_label>
    <arm_group_label>Low Functional Liver Volume Group</arm_group_label>
    <arm_group_label>Prior Liver Directed Radiation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up.</description>
    <arm_group_label>Advanced Cirrhosis Group</arm_group_label>
    <arm_group_label>Low Functional Liver Volume Group</arm_group_label>
    <arm_group_label>Prior Liver Directed Radiation Group</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of hepatocellular carcinoma, cholangiocarcinoma, or liver metastasis from
             any histology

          2. Patients may have single or multinodular tumors

          3. There is no specific tumor size cut-off for this protocol. However, the radiation
             treatment plan must meet the protocol's dose constraints.

          4. Age 18 or older

          5. Compromised liver function as defined by any of the following Cohorts: a. Cohort 1:
             Advanced cirrhosis group; *Borderline Child-Pugh Class A6, *Child-Pugh Class B, *The
             patients in this advanced cirrhosis group must have at least 400 ml of functional
             liver, as estimated on either diagnostic imaging (CT or MRI) or SPECT/CT with Tc-99m
             sulfur colloid. There is no upper limit on the functional liver volume for these
             patients; b. Cohort 2: Low functional liver volume without underlying chronic liver
             disease; *Previous irinotecan or oxaliplatin chemotherapy, *Previous liver
             resection(s), *These patients must have at least 400 ml of functional liver, as
             estimated by either diagnostic imaging computed tomography or magnetic resonance
             imaging (CT or MRI) or SPECT/CT with Tc-99m sulfur colloid. There is no upper limit on
             the functional liver volume for these patients. (continued to criteria #6)

          6. c. Cohort 3: History of of prior liver-directed radiation therapy with either
             fractionated EBRT, SBRT or Y90 RE.The interval between prior EBRT and re-irradiation
             on protocol should be equal to or greater than 12 months. The interval between prior
             Y90 RE and re-irradiation on protocol should be equal to or greater than 6 months.
             *Cirrhosis group: i. Child-Pugh Class A5; ii. Borderline Child-Pugh Class A6; iii. The
             patients in this group must have at least 400 ml of functional liver, as estimated on
             either diagnostic imaging (CT or MRI) or SPECT/CT with Tc-99m sulfur colloid. There is
             no upper limit on the functional liver volume for these patients. (continued to
             criteria #7)

          7. *Low functional liver volume without underlying liver disease. i. Previous irinotecan
             or oxaliplatin chemotherapy; ii. Previous liver resection(s); iii. These patients must
             have at least 400 ml of functional liver, as estimated by either diagnostic imaging
             (CT or MRI) or SPECT/CT with Tc-99m sulfur colloid. There is no upper limit on the
             functional liver volume for these patients

          8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          9. Women of childbearing potential (those who have not undergone a hysterectomy or who
             have not been postmenopausal for at least 24 consecutive months) must agree to
             practice adequate contraception and to refrain from breast feeding.

         10. Prior history of surgical resection, chemotherapy, TACE, and/or radiofrequency
             ablation are allowed.

         11. Expected survival must be greater than 3 months

         12. Patients may receive concurrent capecitabine or sorafenib at the discretion of the
             treating physicians

         13. Signed study-specific consent form

        Exclusion Criteria:

          1. Prior liver-directed radiation therapy for patients in Cohorts 1 (advanced cirrhosis
             group) or cohort 2 (low functional volume group)

          2. Prior Yttrium-90 therapy for patients in cohorts 1 or 2

          3. Patients with a Child-Pugh score less than 6 or greater than 9 for radiation na√Øve
             patients with cirrhosis (cohort 1).

          4. Child-Pugh score of greater than 6 for patients with cirrhosis who previously received
             liver directed radiation (EBRT or Y90 RE) (cohort 3).

          5. Unstable angina, and/or symptomatic congestive heart failure requiring hospitalization
             within the last 6 months. Transmural myocardial infarction within the last 6 months
             prior to study entry.

          6. Current evidence of fever or untreated infection

          7. Active hepatitis, including but not limited to viral and drug-induced

          8. Poorly controlled inflammatory bowel disease

          9. Women with a positive pregnancy test

         10. Inability to comply with study and/or follow-up procedures

         11. Patients with an active second malignancy or prior invasive malignancy unless disease
             free for a minimum of 3 years. Non-melanoma skin cancer and previous early prostate
             cancer that had a non-rising PSA can be enrolled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene J. Koay, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugene J. Koay, MD, PHD</last_name>
    <phone>713-563-2300</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Loyola University Chicago, Cardinal Bernardin Cancer Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD Anderson Health Information Specialist</last_name>
      <phone>877-632-6789</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Cancer</keyword>
  <keyword>Impaired Liver Function</keyword>
  <keyword>Liver tumors</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Low functional liver volume</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>XRT</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Questionnaire</keyword>
  <keyword>Survey</keyword>
  <keyword>High dose radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

